UroToday

PSMA and Beyond 2025: How to Crush a PSMA PET Report: Guidelines and Scoring Systems

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Phillip Kuo discussing guidelines and scoring systems of a PSMA PET report. Dr. Kuo started his ...
UroToday

ESMO 2025: Final Results from PRESTO (AFT-19): A Phase 3 Open-label Study of Combined Androgen Blockade in Patients with High-risk Biochemically Relapsed Prostate Cancer

ESMO 2025 final results of PRESTO (AFT-19), phase III trial of combined androgen blockade in patients with high-risk, biochemically relapsed prostate cancer.
UroToday

IBCN 2024: Spatial Proteomics and Transcriptomics Reveal an Altered Immune Cell Landscape in Bladder Cancer Patients Unresponsive to BCG Treatment

(UroToday.com) The 2024 IBCN annual meeting included a session on treatment response correlates, featuring a presentation by Dr. Trine Strandgaard discussing spatial proteomics and transcriptomics in ...
UroToday

ASCO GU 2026: Discussant: Improving Outcomes for Radiotherapy

(UroToday.com) The 2026 GU ASCO annual meeting featured a prostate cancer session and a discussant presentation by Dr. Bridget Koontz, discussing two abstracts, “Hormone therapy use and duration with ...
UroToday

SNMMI 2025: How About Actinium-225?

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr.
UroToday

European Association of Urology Congress (EAU) 2025 Annual Meeting

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

PSMA and Beyond 2025: Impact of Clinical Guidelines on the Utilization of PSMA PET

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Emmanuel Antonarakis discussing the impact of clinical guidelines on the utilization of PSMA ...
UroToday

PSMA and Beyond 2025: Beyond PSMA in Prostate Cancer: STEAP1, DLL3, and CD46

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...
UroToday

EAU 2026: Treatment of High-grade NMIBC: Results from the VERSUS Study

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non muscle invasive bladder cancer session and a presentation by Dr.
UroToday

Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer in a Prospective Statewide Collaborative

Randy A. Vince Jr., Ralph Jiang, Ji Qi, Jeffrey J. Tosoian, Rebecca Takele, Felix Y. Feng, Susan Linsell, Anna Johnson, Sughand Shetty, Patrick Hurley, David C ...
UroToday

Predictive factors for biochemical recurrence after radical prostatectomy in ISUP Grade Group 1 prostate cancer: a retrospective cohort with long-term follow-up.

The clinical relevance of biochemical recurrence (BCR) after radical prostatectomy (RP) in ISUP Grade Group 1 prostate cancer is unclear. We evaluated the incidence of BCR, its pathological predictors ...
UroToday

PSMA and Beyond 2026: How PCWG4 Impacts Future Trials

(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Michael Morris discussing how PCWG4 impacts future trials. Dr. Morris started his ...